Ruxolitinib is a medication used to manage and treat myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It is in the Janus Kinase inhibitor class of medications. This activity reviews the indications, action, and contraindications for ruxolitinib as a valuable agent in managing myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for members of the interprofessional team in managing patients with myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease and their related conditions.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/131551
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, All Practice Areas (e.g. ethics), Critical Care Medicine, General Pediatrics, General Surgery, Hematology, Hospital Medicine, Internal Medicine, Medical Oncology, Pediatric Hematology-Oncology, Pulmonary Disease, Rheumatology